The studies suggest that mutant KRAS signals predominantly through the rapidly accelerating fibrosarcoma (RAF) effector pathway in pancreatic ductal adenocarcinoma (PDAC) models, with its ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

Murine Kras-driven lung cancer models have confirmed the key requirements for RAF, PI3K and RAL-GEF in vivo. Co-opted pathways required by oncogenic KRAS in order to sustain lung tumorigenesis ...

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS ...

MICAL2 appears to supercharge the KRAS signaling pathway, which regulates cell growth, proliferation, and death and is known to be the primary driver of pancreatic tumor growth and the spread of ...

"Our findings represent a breakthrough in the treatment of HCM in children, particularly those suffering from severe forms of the disease due to genetic variants in the RAS/MAPK pathway," said ...

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S ...